Scarecrows, as you know we must always consider the negatives, no matter how big or small, no matter how trivial, its good to have an understanding of these as well as the positives. Thanks for pointing these out. Also from a lay-person's stance, if patients were on Blood thinners maybe there is some scope to reduce these accordingly if one were to take up the course of iPPS. These considerations will most likely be address in a Phase Three trial, just one reason why the Phase Three will be fairly comprehensive and time consuming. They do of course need to consider it as you say a fair % of older patients could be on such drugs as Warfarin and other medications. It is the multitude of combinations that will be considered and thus one of the reasons a much larger subset of the population is included.
With some 700 odd patients already haven gone through the SAS program so far I wonder if or any of these were on such medications or were they deliberately filtered out at this early SAS program stage?
- Forums
- ASX - By Stock
- Enlighten me please.
Scarecrows, as you know we must always consider the negatives,...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M |
Open | High | Low | Value | Volume |
23.5¢ | 24.0¢ | 22.5¢ | $186.1K | 801.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 33599 | 23.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 65498 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 28599 | 0.230 |
6 | 177453 | 0.225 |
15 | 211076 | 0.220 |
6 | 98958 | 0.215 |
9 | 260864 | 0.210 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 65498 | 1 |
0.240 | 7432 | 3 |
0.245 | 48923 | 2 |
0.250 | 18443 | 2 |
0.260 | 58362 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online